Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Olokizumab in Rheumatoid Arthritis Inadequately Controlled by Methotrexate
2014-004719-36Phase 3Completed
- Sponsor
- R-Pharm
- Start
- Apr 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of olokizumab in rheumatoid arthritis (RA) (3 arms), sponsored by R-Pharm. Primary endpoint: Primary efficacy endpoint. Started Apr 2016; status: completed.
02
Drugs
olokizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2014-004719-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004719-36.